| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEWS |
From the Departments of Obstetrics and Gynecology, Medical Oncology, and Pathology, University Hospital Groningen, Groningen, The Netherlands.
Address reprint requests to: Marian J. E. Mourits, MD, Department of Obstetrics and Gynecology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands, E-mail: m.j.e.mourits{at}og.azg.nl
Objective: To review the literature on tamoxifen side effects on the female genital tract and psychosexual function in premenopausal and postmenopausal women.
Data Sources: We used the English-language literature in MEDLINE and reference lists from selected articles. Search terms included: "tamoxifen and estrogen receptor," "transcription activation," "premenopause," "postmenopause," "vaginal epithelium," "uterus," "endometrial hyperplasia," "polyps," "endometrial cancer," "sonography," "sonohysterography," "hysteroscopy," "myometrium," "myoma," "sarcoma," "endometriosis," "ovarian cysts," "hot flushes," "concentration problems," "sleep disturbance," "vaginal dryness," "sexual function," "libido," "dyspareunia," and "quality of life." No study-type restrictions were imposed.
Methods of Study Selection: With respect to clinical studies we included case cohort studies, observational studies; if no trials were available on a subject, case reports published in peer-reviewed journals were selected. For the discussion on endometrial surveillance of tamoxifen users, letters and editorials published in peer-reviewed journals also were used. Subjects of interest were mechanism of action of tamoxifen, tamoxifen and the vaginal epithelium, endometrium, mesenchymal tumors of the uterus, ovaries, sexual function, and vasomotor instability.
Tabulation, Integration, and Results: Eligible studies were analyzed to determine their usefulness in this review. Data from trials that evaluated tamoxifen side effects on specific genital tissues were combined, with special interest in differentiation of side effects in premenopausal and postmenopausal women. Weighted estimates of severity and extent of side effects were usually not possible because of lack of randomized trials. Only the risk of endometrial cancer in relation to tamoxifen treatment could be estimated.
Conclusion: The gynecologic side effects of tamoxifen are diverse and reflect the complexity of its mechanism of action, with agonistic and antagonistic effects on various tissues, depending on the ambient estradiol concentration and hence menopausal status of the patient. The most frequently reported side effect was hot flushes, and the most worrisome gynecologic side effect was a two- to three-fold increased risk of endometrial cancer in postmenopausal women. Despite its side effects, the benefits of tamoxifen in controlling breast cancer or prevention of its relapse are still without debate.
This article has been cited by other articles:
|
|
 |
|
  H. K. Choi, S. H. Roh, H. G. Kim, E. H. Han, H. G. Jeong, and K. W. Kang Enhanced expression of aromatase in p53-inactivated mammary epithelial cells Endocr. Relat. Cancer, March 1, 2008; 15(1): 139 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Rock, S. W. Flatt, G. A. Laughlin, E. B. Gold, C. A. Thomson, L. Natarajan, L. A. Jones, B. J. Caan, M. L. Stefanick, R. A. Hajek, et al. Reproductive Steroid Hormones and Recurrence-Free Survival in Women with a History of Breast Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 614 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T M Sadler, M Gavriil, T Annable, P Frost, L M Greenberger, and Y Zhang Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr. Relat. Cancer, September 1, 2006; 13(3): 863 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Kaplan, J. S. Haas, E. J. Perez-Stable, S. E. Gregorich, C. Somkin, G. Des Jarlais, and K. Kerlikowske Breast Cancer Risk Reduction Options: Awareness, Discussion, and Use among Women from Four Ethnic Groups Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 162 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C.J.P. Gielen, C. W. Burger, L. C.M. Kuhne, P. Hanifi-Moghaddam, and L. J. Blok Analysis off Estrogen Agonism and Antagonism of Tamoxifen, Raloxifene, and ICI182780 in Endometrial Cancer Cells: A Putative Role for the Epidermal Growth Factor Receptor Ligand Amphiregulin Reproductive Sciences, October 1, 2005; 12(7): e55 - e66. [Abstract] [PDF]
|
|
|
|
 |
|
 B. S. Komm, Y. P. Kharode, P. V. N. Bodine, H. A. Harris, C. P. Miller, and C. R. Lyttle Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity Endocrinology, September 1, 2005; 146(9): 3999 - 4008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Oktay, E. Buyuk, N. Libertella, M. Akar, and Z. Rosenwaks Fertility Preservation in Breast Cancer Patients: A Prospective Controlled Comparison of Ovarian Stimulation With Tamoxifen and Letrozole for Embryo Cryopreservation J. Clin. Oncol., July 1, 2005; 23(19): 4347 - 4353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Rock, S. W. Flatt, C. A. Thomson, M. L. Stefanick, V. A. Newman, L. A. Jones, L. Natarajan, C. Ritenbaugh, K. A. Hollenbach, J. P. Pierce, et al. Effects of a High-Fiber, Low-Fat Diet Intervention on Serum Concentrations of Reproductive Steroid Hormones in Women With a History of Breast Cancer J. Clin. Oncol., June 15, 2004; 22(12): 2379 - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Curtis, D. M. Freedman, M. E. Sherman, and J. F. Fraumeni Jr. Risk of Malignant Mixed Mullerian Tumors After Tamoxifen Therapy for Breast Cancer J Natl Cancer Inst, January 7, 2004; 96(1): 70 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-K. Chang, P. Chen, F.-J. Leu, and S. M. A. Lou Florid Polypoid Endometriosis Exacerbated by Tamoxifen Therapy in Breast Cancer Obstet. Gynecol., November 1, 2003; 102(5): 1127 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Modugno, R. B. Ness, S. Ewing, and J. A. Cauley Effect of Raloxifene on Sexual Function in Older Postmenopausal Women With Osteoporosis Obstet. Gynecol., February 1, 2003; 101(2): 353 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Oktay, E. Buyuk, O. Davis, I. Yermakova, L. Veeck, and Z. Rosenwaks Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen Hum. Reprod., January 1, 2003; 18(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
